Shire Licenses Parion’s P-321 for Dry Eye Disease

May 12, 2017: By Joan McKenna

ShireShire has signed an exclusive global licensing agreement to develop and commercialize Parion Sciences’ P-321 for dry eye disease in adults, the two companies announced May 1.

P-321 is an epithelial sodium channel (ENaC) inhibitor in Phase II development as a topical treatment to address tear volume deficiency and promote ocular surface healing.

Shire will make an initial $20 million up-front payment, plus a potential near-term milestone payment of $20 million, to lead development of P-321.

Parion is entitled to additional milestone payments, and the deal has a potential total value of $535 million.

Parion, of Durham, NC, has the option to co-fund development through later stages in exchange for royalties. In addition, Parion has the option to co-fund and benefit from commercialization.

Shire, headquartered in Dublin, launched Xiidra for dry eye disease—its first ophthalmic product—in August 2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Quidel Acquires RPS’ InflammaDry, AdenoPlus Ophthalmic Diagnostic Tests

Gottlieb Says US FDA Can Help Reduce Drug Prices through Generics, Biosimilars

ONL Therapeutics Closes $4.25 Million Series A Financing

Omeros’ Omidria Revenues Total $12.3 Million in Q1-2017

Finland Eye Care Provider Silmäasema Oyj Plans IPO to Raise €35 Million

Alcon Introduces SYSTANE ICAPS Chewable Eye Vitamin

Aerie’s Rhopressa Gets Target Action Date from US FDA

STAAR’s EVO+ Visian ICL with Aspheric (EDOF) Optic Receives CE Mark Approval

Refocus to File for US Approval of VisAbility for Presbyopia in Q3-2017

Trial for James Mazzo Ends in Hung Jury; Co-defendants DeCinces, Parker Convicted

Alcon Names Stephen S. Lane, MD, as Chief Medical Officer

Allergan’s Restasis Sales Increase 3.4 Percent in Q1-2017

Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

Carl Zeiss Meditec’s Revenues Grow 8.6 percent in First Half of Fiscal Year

Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

Shire Licenses Parion’s P-321 for Dry Eye Disease

Imprimis’ Ophthalmic Sales Grow 105 Percent in Q1-2017

Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

Coming soon

2017 Ophthalmic Laser Report: A Global Market Analysis for 2016 to 2022 (Photocoagulation, Photodisruption, and SLT)